| 1 |
35604822 | A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance. | 2022 May 23 |
2 |
| 2 |
32381576 | Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers. | 2021 Apr 1 |
1 |
| 3 |
33289516 | Bortezomib limits renal allograft interstitial fibrosis by inhibiting NF-κB/TNF-α/Akt/mTOR/P70S6K/Smurf2 pathway via IκBα protein stabilization. | 2021 Jan 15 |
4 |
| 4 |
33406639 | Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. | 2021 Jan 4 |
4 |
| 5 |
33572814 | HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma. | 2021 Jan 29 |
1 |
| 6 |
33674562 | Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling. | 2021 Mar 5 |
3 |
| 7 |
33787860 | Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. | 2021 Apr 13 |
1 |
| 8 |
33973606 | The TiO2-μ implant residual is more toxic than the Al2O3-n implant residual via blocking LAP and inducing macrophage polarization. | 2021 May 20 |
1 |
| 9 |
34390764 | Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. | 2021 Nov 1 |
1 |
| 10 |
34501388 | Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. | 2021 Aug 31 |
2 |
| 11 |
34571936 | Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation. | 2021 Sep 2 |
1 |
| 12 |
32142770 | Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity. | 2020 May 15 |
2 |
| 13 |
32160736 | PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest | 2020 Aug 28 |
2 |
| 14 |
32683901 | Proteasomal Inhibition Potentiates Latent HIV Reactivation. | 2020 Oct |
1 |
| 15 |
33187351 | Supramolecular Caffeic Acid and Bortezomib Nanomedicine: Prodrug Inducing Reactive Oxygen Species and Inhibiting Cancer Cell Survival. | 2020 Nov 11 |
1 |
| 16 |
33191863 | Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway. | 2020 Dec |
2 |
| 17 |
33214335 | CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-κB pathway in Burkitt lymphoma. | 2020 Aug |
1 |
| 18 |
33330064 | Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways. | 2020 |
2 |
| 19 |
31347196 | Platycodin D inhibits proliferation, migration and induces chemosensitization through inactivation of the NF-κB and JAK2/STAT3 pathways in multiple myeloma cells. | 2019 Dec |
1 |
| 20 |
31631595 | [Bortezomib Inhibits Extranodal Natural Killer/T Cell Lymphoma, Nasal Type by Targeting NF-κB Signaling Pathway]. | 2019 May |
3 |
| 21 |
29279332 | Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. | 2018 Feb 16 |
5 |
| 22 |
29441489 | Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway. | 2018 Sep |
4 |
| 23 |
29468963 | NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives. | 2018 |
1 |
| 24 |
29695239 | Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. | 2018 Apr 25 |
1 |
| 25 |
29699990 | TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia. | 2018 Jun 21 |
1 |
| 26 |
30487672 | Ameliorating effects of bortezomib, a proteasome inhibitor, on development of dextran sulfate sodium-induced murine colitis. | 2018 Nov |
1 |
| 27 |
33445276 | Bortezomib Increases the Cancer Therapeutic Efficacy of Poly(amino acid)-Doxorubicin. | 2018 Jun 11 |
2 |
| 28 |
27923823 | Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. | 2017 Jan |
1 |
| 29 |
28339079 | A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-κB. | 2017 May |
3 |
| 30 |
29386876 | Bortezomib inhibits proliferation, migration, and TGF-β1-induced epithelial-mesenchymal transition of RPE cells. | 2017 |
2 |
| 31 |
26227222 | Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi. | 2016 Jan |
1 |
| 32 |
26683226 | MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment. | 2016 Jan 26 |
1 |
| 33 |
27016342 | Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. | 2016 Sep |
2 |
| 34 |
27300524 | A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. | 2016 Aug |
2 |
| 35 |
27806331 | XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. | 2016 Nov 29 |
2 |
| 36 |
25363231 | NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. | 2015 Mar |
1 |
| 37 |
25613668 | TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. | 2015 Apr |
2 |
| 38 |
25661379 | Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species. | 2015 Feb |
5 |
| 39 |
25686825 | NF-κB signaling mediates acquired resistance after PARP inhibition. | 2015 Feb 28 |
1 |
| 40 |
25766331 | NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. | 2015 Mar 12 |
7 |
| 41 |
25823927 | Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target. | 2015 Mar 20 |
3 |
| 42 |
25895124 | Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. | 2015 Apr 20 |
1 |
| 43 |
26099967 | The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. | 2015 Aug |
2 |
| 44 |
26431276 | Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk. | 2015 Oct 20 |
4 |
| 45 |
26494122 | Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. | 2015 Dec 15 |
1 |
| 46 |
27358886 | Current approaches and advance in mantle cell lymphoma treatment. | 2015 |
1 |
| 47 |
23697845 | Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. | 2014 Feb |
5 |
| 48 |
24262132 | Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB. | 2014 Jan |
1 |
| 49 |
24286313 | Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. | 2014 May |
2 |
| 50 |
24481412 | IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. | 2014 Apr |
7 |